(Q33185503)

23 July 2017

0 references

Risk factors for failure of Helicobacter pylori therapy--results of an individual data analysis of 2751 patients (English)

1 reference

Helicobacter pylori infectious disease

23 July 2017

0 references

0 references

1 reference

Broutet N

1

1 reference

23 July 2017

Tchamgoué S

2

1 reference

23 July 2017

Pereira E

3

1 reference

23 July 2017

Lamouliatte H

4

1 reference

23 July 2017

Salamon R

5

1 reference

23 July 2017

Mégraud F

6

1 reference

23 July 2017

language of work or name

English

0 references

publication date

1 January 2003

1 reference

Alimentary Pharmacology & Therapeutics

23 July 2017

1 reference

23 July 2017

17

1 reference

23 July 2017

1

1 reference

23 July 2017

99-109

1 reference

One-week ranitidine bismuth citrate in combinations with metronidazole, amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection: the RBC-MACH study.

23 July 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01396.X

A systematic review of Helicobacter pylori eradication therapy--the impact of antimicrobial resistance on eradication rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01396.X

cagA Status and eradication treatment outcome of anti-Helicobacter pylori triple therapies in patients with nonulcer dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01396.X

Importance of Helicobacter pylori cagA and vacA status for the efficacy of antibiotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01396.X

Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01396.X

Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01396.X

Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01396.X

Treatment after failure: the problem of "non-responders".

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01396.X

Role of tight junctions in establishing and maintaining cell polarity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01396.X

Interactions between H. pylori infection, gastric acid secretion and anti-secretory therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01396.X

Meta-analysis of risk factors for peptic ulcer. Nonsteroidal antiinflammatory drugs, Helicobacter pylori, and smoking

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01396.X

10.1046/J.1365-2036.2003.01396.X

21 January 2018

Identifiers

DOI

1 reference

23 July 2017

1 reference